Differences in systemic treatments for breast cancer between patients with and without diabetes
Women with diabetes are less likely to be treated with chemotherapy, and the difference is greatest in Pacific women and patients with stage II breast cancer. The lower usage of endocrine therapy and HER2-targeted therapy in patients with diabetes could be explained by the older age at diagnosis and more comorbidities.
Authors
- Jason Gurney (ORCID: https://orcid.org/0000-0002-7615-0748)
- James Stanley (ORCID: https://orcid.org/0000-0002-8572-1047)
- Jeremy Krebs (ORCID: https://orcid.org/0000-0002-7850-3447)
- Andrea Teng (ORCID: https://orcid.org/0000-0002-6116-3941)
- Ross Lawrenson (ORCID: https://orcid.org/0000-0003-0437-8839)
- Dianne Sika‐Paotonu (ORCID: https://orcid.org/0000-0003-1930-1551)
- Marion Kuper‐Hommel (ORCID: https://orcid.org/0000-0002-1719-7052)
- Chunhuan Lao (ORCID: https://orcid.org/0000-0002-2319-8916)
- Jeannine Stairmand (ORCID: https://orcid.org/0000-0002-1754-902X)
- Ian Campbell
- Jonathan Koea
Institutions
- University of Otago (NZ)
Publication Details
- Journal
- New Zealand Medical Journal
- Published
- 2025-04-09
- DOI
- https://doi.org/10.26635/6965.6765
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Otago
- University of Waikato
- University of Auckland